Experimental Protocol
Two-hour middle cerebral artery occlusion and reperfusion were induced by a modified microcatheter model. 3 Before reperfusion, 0.9% cold (0°C) saline or human Alb (0°C or 37°C; Tian Tan Biotherapeutic Corp, 20% solution) was infused. Animals were randomly divided into 6 groups: (1) non-treatment group (n=8): 2-hour middle cerebral artery occlusion followed by 48 hours of reperfusion; (2) local cold (0°C) saline infusion group (0.9% saline, n=12); (3) local low-dose cold (0°C) human Alb infusion group (0.5 g/kg, n=12); (4) local low-dose normothermic (37°C) human Alb infusion group (0.5 g/ kg, n=12); (5) systemic low-dose normothermic (37°C) human Alb infusion group (0.5 g/kg, n=8) applied through the femoral artery; (6) systemic high-dose normothermic (37°C) human Alb infusion group (1.5 g/kg, n=12). All treatments, examinations, and evaluations were performed by investigators blinded to the groups.
Neurological and Behavioral Examination
After ischemia-reperfusion, neurological deficits were scored. 6 Animals were also examined with motor testing paradigms (foot-fault placing, parallel-bar crossing, and ladder and rope climbing). 2
Cerebral Infarct Volume
Brain slices were treated with 2,3,5-triphenyltetrazolium chloride (TTC, Sigma, St. Louis, MO), and an indirect method for calculating infarct volume was used. 7
Statistical Analysis
The values are expressed as means±SEM. Differences between 2 groups and differences between multiple groups were evaluated using a Student t test or 1-way ANOVA, respectively, with a significance level at P<0.05. Post hoc comparison between groups was further performed using the least significant difference method.
Results

Regional Brain Hypothermia
In <3 minutes, the local 0°C Alb or saline solution infusion significantly (P<0.01) reduced the temperature of the
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Conclusions-The
Cerebral Lesion Volume
Infarction volume in the nontreatment group was 61.6±10.8%. Although the measured lesion volume in the systemic lowdose normothermic Alb infusion group (52.5±5.6%) was reduced when compared with the nontreatment group, the reduction did not reach a significant level. Compared with the nontreatment group, the lesion volume was 35.4±6.6% (−43%) in animals treated with a local 37°C Alb (0.5 g/kg) infusion, 41.7±6.4 (−32%) with a local 0°C saline infusion, 38.8±5.8 (−37%) with a systemic 37°C Alb (1.5 g/kg) infusion, and 20.3±8.7 (−67%) with a local 0°C Alb (0.5 g/kg) infusion. The local cold Alb infusion resulted in the greatest (P<0.01) reduction in lesion volume (Figure 1 ).
Functional Outcome
Animals in all groups exhibited severe neurological deficits at 30 minutes after the 2-hour middle cerebral artery occlusion, with no significant differences between groups (Figure 2) . After 24 and 48 hours of reperfusion, the systemic lowdose normothermic Alb infusion group failed to demonstrate improved recovery of neurological and motor function (Figures 2 and 3 ). However, rats in the other 4 groups showed (Figures 2 and 3 , P<0.01) improvements in neurological and motor function. Furthermore, the rats that received local cold Alb (0.5 g/kg) infusion therapy had the best recovery (P<0.05).
Discussion
In this study, we demonstrated a synergistic effect of regional brain hypothermia and low-dose Alb infusion in acute ischemic stroke.In several previous clinical trials of preclinically promising neuroprotectants, the substances failed to earn clinical approval because of the pronounced side effects of therapeutic doses. 8, 9 A recent study suggests that elective intra-arterial drug injection might result in high local drug 10 In the present study, because the Alb solution was directly infused into the ischemic cerebral area, a low dose still conferred neuroprotection as significant as that achieved by systemic administration of high-dose Alb. Clinically, a local low-dose Alb infusion would reduce the risk of adverse dose-related systemic effects seen more frequently with high-dose systemic Alb infusions. In the present study, regional brain hypothermia was induced by local intra-arterial infusion with a small amount of cold Alb solution. This method produced hypothermia much faster than systemically induced whole body hypothermia, so as not to miss the therapeutic window. 11 The present study showed acute neuroprotection, however long-term neuroprotection remains to be investigated. Because a great variety of endovascular tools exist for delivering medications to intracranial vessels, this protocol, combined with intra-arterial thrombolysis or mechanical embolectomy, could be functionally applied in the clinical setting. 
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